| Event Time: |
Sunday May 5, 2019 1:00 pm to 3:00 pm |
| Topic(s): |
MS and CNS Inflammatory Disease, Advanced Practice Provider |
| Director(s): |
Scott Newsome DO, FAAN |
| Description: |
The use of disease-modifying treatments (DMTs) in MS is one of the most rapidly evolving therapeutic areas in neurology. As new and arguably more effective treatments have become available, decision-making in regard to MS DMTs has become much more complex for both neurologists and people with MS. This course will review the mechanisms of action and the risk-benefit ratios of the DMTs and delve into different treatment paradigms, risk mitigation strategies, sequencing considerations, and shared decision-making. This program complements Multiple Sclerosis Therapy: Disease-modifying Treatment II, but covers independent topics. |
| Completion Message: |
Participants should be familiar with the indications and risks associated with approved disease-modifying agents in multiple sclerosis, and be better able to identify the appropria |
